The biotechnology company Domainex has secured further financing to develop its Combinatorial Domain Hunting (CDH) technology, and to advance its internal pipeline of oncology targets. The patented CDH technology puts Domainex in a strong position to clone and express challenging protein drug targets. This funding will be used to develop the company’s small-molecule drug research portfolio, consisting of the kinase IKKe, and a number of methyltransferase enzymes. The two-stage funding round involves investment from Longbow, The Capital Fund, and Takeda Research Investment, Inc. (TRI).
Eddy Littler, CEO of Domainex, said, “The involvement of TRI represents an important recognition of the value of Domainex’s unique CDH technology, and its novel oncology pipeline. We are eagerly looking forward to the next few months during which we anticipate advancing our targets and pipeline to an exciting position. We will of course continue to develop our CDH technology, and will collaborate with Takeda on a number of innovative drug discovery targets”.
Graeme Martin, President & CEO of TRI said “CDH is a truly innovative technology and highly complimentary to Takeda’s existing structural biology initiatives. Our investment in Domainex is intended to help the company further develop this platform, and typifies TRI’s commitment to supporting therapeutic innovation in creative, early stage companies”.